Salirasib , ≥98% , 162520-00-5

Synonym(s):
2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid;Farnesylthiosalicylic acid;FTS;S-Farnesylthiosalicylic acid

CAS NO.：162520-00-5

Empirical Formula: C22H30O2S

Molecular Weight: 358.54

MDL number: MFCD00467723

PRODUCT Properties

• Melting point: 64-66°C
• Boiling point: 486.0±45.0 °C(Predicted)
• Density: 1.05
• storage temp.: -20°C
• solubility: DMSO: soluble20mg/mL, clear
• pka: 3.50±0.36(Predicted)
• form: powder
• color: white to beige
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
• InChI: InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
• InChIKey: WUILNKCFCLNXOK-CFBAGHHKSA-N
• SMILES: C(O)(=O)C1=CC=CC=C1SC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/C

Description and Uses

Association of Ras protein with the inner surface of the plasma membrane is required for Ras signaling activity. Farnesyl thiosalicylic acid (FTS) is an inhibitor of Ras-mediated signaling that functions by dislodging Ras from the cell membrane thereby rendering it susceptible to proteolytic degradation. FTS inhibits the growth of human Ha-ras-transformed Rat1 fibroblasts with an IC₅₀ value of 7.5 μM. It does not inhibit Ras farnesylation in vitro and although FTS does inhibit prenylated protein methyltransferase (PPMTase) in cell-free systems with a K_i value of 2.6 μM, it is relatively ineffective at inhibiting methylation in whole cells. Treatment of chow-fed ApoE-deficient mice with 5 mg/kg FTS three times per week for six weeks reduces early atherosclerotic lesion development by 52% compared to controls.

Salirasib has been used as a farnesyltransferase inhibitor.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H319-H315
• Precautionary statements: P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P
• HS Code: 2930.90.2900